Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Capsida Biotherapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This singular focus indicates that the company's current prosecution activity is concentrated on a specific technical matter rather than a broad array of simultaneous filings.
The busiest examiner for this portfolio is BOESEN, AGNIESZKA, who is responsible for 1 busiest examiner pending action. As there is only 1 pending office action in total, BOESEN, AGNIESZKA is the only examiner currently reviewing the company's applications. This creates a direct relationship between the applicant and a single official within the Biotechnology & Pharmaceuticals sector.
With 1 distinct art unit involved, the prosecution is subject to the specific guidelines and precedents of that individual unit. The company's immediate patenting goals are tied to the resolution of the active filing. This streamlined workload allows for a concentrated effort to address the specific requirements of the single examiner and art unit currently engaged with the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 1 | 68.6% | +21.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692014 | VIRUS COMPOSITIONS TO EFFICIENTLY TARGET THE NERVOUS SYSTEM AND THE LUNGS | BOESEN, AGNIESZKA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692014 | VIRUS COMPOSITIONS TO EFFICIENTLY TARGET THE NERVOUS SYSTEM AND THE LUNGS | BOESEN, AGNIESZKA | 1632 | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCapsida Biotherapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Agnieszka Boesen has the most, with 1 of Capsida Biotherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
